Drug intelligence / Profile preview

RA 233

Development stage: Discontinued
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

RA 233 is a pyrimido-pyrimidine derivative and an antiplatelet drug, chemically related to dipyridamole. It was investigated in a placebo-controlled, double-blind, multicenter study for its efficacy in ovarian cancer. Patients received RA 233 or placebo for 2 years following primary surgery and combination cytotoxic chemotherapy. The study concluded that long-term administration of RA 233 offered no clinical benefit in ovarian cancer, showing no significant differences in new metastases, progressive malignancy growth, or survival compared to placebo-treated patients.

Targets

CNT2 (Concentrative nucleoside transporter 2)

Beyond the preview

Go deeper on RA 233.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RA 233.

Explore the full profile